Benjamin Carr, Ph.D. 👨🏻💻🧬#Chemo drug shortage shows vulnerability of the #healthcare #supplychain
As #cisplatin became scarce, oncologists switched to #carboplatin, another common #cancer therapy, which Intas also produced. With Intas no longer producing carboplatin & increasing demand, that medicine is now also in short supply. It was “like a ripple effect in the supply chain,” Socal says.
Survey of US cancer centers in May revealed that a whopping 93% were experiencing shortages of carboplatin.
https://www.technologyreview.com/2023/08/18/1078108/cancer-drug-shortage-supply-chain/
As #cisplatin became scarce, oncologists switched to #carboplatin, another common #cancer therapy, which Intas also produced. With Intas no longer producing carboplatin & increasing demand, that medicine is now also in short supply. It was “like a ripple effect in the supply chain,” Socal says.
Survey of US cancer centers in May revealed that a whopping 93% were experiencing shortages of carboplatin.
https://www.technologyreview.com/2023/08/18/1078108/cancer-drug-shortage-supply-chain/
